Healius Past Earnings Performance

Past criteria checks 0/6

Healius's earnings have been declining at an average annual rate of -56.2%, while the Healthcare industry saw earnings growing at 1.5% annually. Revenues have been growing at an average rate of 3.2% per year.

Key information

-56.2%

Earnings growth rate

-57.0%

EPS growth rate

Healthcare Industry Growth	2.4%
Revenue growth rate	3.2%
Return on equity	-93.7%
Net Margin	-58.2%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Healius makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ASX:HLS Revenue, expenses and earnings (AUD Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	1,692	-984	79
30 Sep 23	1,699	-682	79
30 Jun 23	1,707	-380	79
31 Dec 22	1,839	35	90
30 Sep 22	2,064	164	100
30 Jun 22	2,289	292	110
31 Dec 21	2,292	226	106
30 Sep 21	2,103	146	96
30 Jun 21	1,914	66	86
31 Mar 21	1,802	75	90
31 Dec 20	1,690	83	93
30 Sep 20	1,630	83	87
30 Jun 20	1,570	83	82
31 Dec 19	1,502	110	227
30 Sep 19	1,534	83	226
30 Jun 19	1,566	57	225
31 Mar 19	1,785	29	269
31 Dec 18	1,752	2	259
30 Sep 18	1,728	3	251
30 Jun 18	1,705	4	244
31 Mar 18	1,694	-256	241
31 Dec 17	1,683	-516	238
30 Sep 17	1,671	-516	238
30 Jun 17	1,659	-517	238
31 Mar 17	1,648	-260	223
31 Dec 16	1,637	-3	209
30 Sep 16	1,639	18	209
30 Jun 16	1,642	38	209
31 Dec 15	1,595	126	183
30 Sep 15	1,587	121	183
30 Jun 15	1,580	117	183
31 Mar 15	1,596	127	185
31 Dec 14	1,572	118	178
30 Sep 14	1,548	116	178
30 Jun 14	1,524	115	178
31 Mar 14	1,501	134	144
31 Dec 13	1,478	131	140
30 Sep 13	1,459	140	140
30 Jun 13	1,440	150	140

Quality Earnings: HLS is currently unprofitable.

Growing Profit Margin: HLS is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: HLS is unprofitable, and losses have increased over the past 5 years at a rate of 56.2% per year.

Accelerating Growth: Unable to compare HLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HLS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-19.1%).

Return on Equity

High ROE: HLS has a negative Return on Equity (-93.7%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Healius Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

Consensus EPS estimates increase by 34%

Consensus EPS estimates increase by 36%

Consensus EPS estimates increase by 22%

High number of new directors

Consensus EPS estimates increase by 18%

Is Healius Limited (ASX:HLS) Trading At A 50% Discount?

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Consensus EPS estimates increase by 17%

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Consensus EPS estimates fall by 21%

At AU$3.07, Is It Time To Put Healius Limited (ASX:HLS) On Your Watch List?

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Consensus forecasts updated

Price target decreased to AU$3.23

Consensus EPS estimates fall by 13%

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 27%

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Is Now An Opportune Moment To Examine Healius Limited (ASX:HLS)?

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

MD, CEO & Director exercised options to buy AU$2.2m worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Are Investors Undervaluing Healius Limited (ASX:HLS) By 48%?

Healius Reportedly Launches Day Surgery Sale Process

Price target decreased to AU$4.30

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Consensus EPS estimates fall by 13%

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Why Healius Limited (ASX:HLS) Could Be Worth Watching

Healius Reportedly Seeks X-Ray Factor in Day Surgeries Sale Plan

Healius Limited's (ASX:HLS) Prospects Need A Boost To Lift Shares

Healius Limited Announces Appointment of John Mattick as Non-Executive Director

Upcoming dividend of AU$0.10 per share

Consensus EPS estimates fall by 11%

Price target decreased to AU$4.94

Healius (ASX:HLS) Is Paying Out A Larger Dividend Than Last Year

First half 2022 earnings: EPS and revenues miss analyst expectations

Healius Limited Announces Ordinary Fully Paid Dividend for the Period of Six Months December 31, 2021, Payable April 15, 2022

Healius Limited to Report First Half, 2022 Results on Feb 23, 2022

Healius Limited (ASX:HLS) acquired Agilex Biolabs Pty Ltd.

Consensus EPS estimates increase by 20%

Healius Limited (ASX:HLS) entered into an agreement to acquire Agilex Biolabs Pty Ltd for approximately AUD 300 million.

MD, CEO & Director recently sold AU$713k worth of stock

Revenue & Expenses Breakdown
Beta